These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 29723161)
21. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network. Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532 [TBL] [Abstract][Full Text] [Related]
22. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Sekhar RV; Jahoor F; Iyer D; Guthikonda A; Paranilam J; Elhaj F; Coraza I; Balasubramanyam A Metabolism; 2012 Oct; 61(10):1395-403. PubMed ID: 22542724 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105 [TBL] [Abstract][Full Text] [Related]
24. Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior. Schlögl H; Müller K; Horstmann A; Miehle K; Püschel J; Villringer A; Pleger B; Stumvoll M; Fasshauer M Diabetes; 2016 Aug; 65(8):2179-86. PubMed ID: 27207511 [TBL] [Abstract][Full Text] [Related]
25. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Oral EA; Gorden P; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Brown RJ Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888 [TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199 [TBL] [Abstract][Full Text] [Related]
27. Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment. Püschel J; Miehle K; Müller K; Villringer A; Stumvoll M; Fasshauer M; Schlögl H Cytokine; 2019 Jan; 113():400-404. PubMed ID: 30539782 [TBL] [Abstract][Full Text] [Related]
28. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy. Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608 [TBL] [Abstract][Full Text] [Related]
29. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. Lebastchi J; Ajluni N; Neidert A; Oral EA J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101 [TBL] [Abstract][Full Text] [Related]
30. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes. Kushchayeva YS; Kushchayev SV; Startzell M; Cochran E; Auh S; Dai Y; Lightbourne M; Skarulis M; Brown RJ J Clin Endocrinol Metab; 2019 Jun; 104(6):2216-2228. PubMed ID: 30657911 [TBL] [Abstract][Full Text] [Related]
31. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723 [TBL] [Abstract][Full Text] [Related]
32. Physiological responses to leptin levels in lipodystrophy: a model for other hypoleptinemias? Rosenbaum M; Leibel RL J Clin Invest; 2018 Aug; 128(8):3237-3239. PubMed ID: 30010621 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872 [TBL] [Abstract][Full Text] [Related]
34. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250 [TBL] [Abstract][Full Text] [Related]